# DALY II USA/ MB-CART2019.1 for DLBCL

> **NCT04792489** · PHASE2 · RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 248 (estimated)

## Conditions studied

- Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B Cell Lymphoma
- High Grade B-cell Lymphoma (HGBCL)
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Transformed Lymphoma
- Central Nervous System Lymphoma
- Mantle Cell Lymphoma (MCL)
- Richter Transformation

## Interventions

- **BIOLOGICAL:** zamtocabtagene autoleucel (MB-CART2019.1)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04792489
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792489, "DALY II USA/ MB-CART2019.1 for DLBCL". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04792489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*